← Back to headlines
Harvard Bioscience Exceeds Q2 Estimates and Raises 2026 Revenue Guidance
Harvard Bioscience reported better-than-expected results for its second quarter and subsequently raised its revenue guidance for the year 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
